0001140361-21-006738.txt : 20210301
0001140361-21-006738.hdr.sgml : 20210301
20210301191245
ACCESSION NUMBER: 0001140361-21-006738
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210225
FILED AS OF DATE: 20210301
DATE AS OF CHANGE: 20210301
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Attar Eyal C.
CENTRAL INDEX KEY: 0001789076
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39069
FILM NUMBER: 21700457
MAIL ADDRESS:
STREET 1: 535 BOYLSTON STREET
CITY: BOSTON
STATE: MA
ZIP: 02116
FORMER NAME:
FORMER CONFORMED NAME: Attar Eyal
DATE OF NAME CHANGE: 20190923
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aprea Therapeutics, Inc.
CENTRAL INDEX KEY: 0001781983
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 535 BOYLSTON STREET
CITY: BOSTON
STATE: MA
ZIP: 02116
BUSINESS PHONE: 6095104718
MAIL ADDRESS:
STREET 1: 535 BOYLSTON STREET
CITY: BOSTON
STATE: MA
ZIP: 02116
4
1
form4.xml
FORM 4
X0306
4
2021-02-25
0001781983
Aprea Therapeutics, Inc.
APRE
0001789076
Attar Eyal C.
535 BOYLSTON STREET
BOSTON
MA
02116
true
SVP, Chief Medical Officer
Common Stock
2021-02-25
4
A
0
33000
0
A
33000
D
Common Stock
2021-02-25
4
A
0
75000
0
A
108000
D
Common Stock
200
I
By adult child
Common Stock
200
I
By child
Stock Option (right to Buy)
6
2021-02-25
4
A
0
143000
0
A
2031-02-25
Common Stock
143000
143000
D
These shares represent restricted stock units which were granted on February 25, 2021, and which will vest and be settled in common stock as follows: (i) 11,000 shares on February 25, 2022, (ii) 11,000 shares on February 25, 2023 and (iii) 11,000 shares on February 25, 2024, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
These shares represent restricted stock units which were granted on February 25, 2021, and which will vest and be settled in common stock as follows: (i) 25,000 shares on August 25, 2021, (ii) 25,000 shares on February 25, 2022 and (iii) 25,000 shares on August 25, 2022, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
Twenty-five percent of these options vest on February 25, 2022, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting date and subject to acceleration under certain conditions.
The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.
/s/ Scott M. Coiante, attorney-in-fact
2021-03-01